📩 Book a meeting with us today: BD-Licensing@biocytogen.com
We’re excited to participate in BIO US 2025 in Boston, MA, from June 16–19! Visit our team to explore how we’re accelerating drug discovery with advanced antibody discovery platforms, humanized models, and comprehensive preclinical solutions.
This event offers a prime opportunity for scientists, biotech leaders, investors, and industry professionals to connect, exchange ideas, and drive collaborations that shape the future of biomedical research.
What is BIO US?
The BIO International Convention is the world’s largest biotech event, uniting 20,000 global leaders to showcase health, agriculture, and sustainability innovations. It offers unmatched networking, including the exclusive BIO Partnering™ platform, making it a key hub for collaboration and industry growth.
Event Overview
Date: June 16, 2025 - June 19, 2025
Venue: Boston Convention & Exhibition Center, 415 Summer St, Boston, MA
Event Schedule
The BIO US 2025 includes keynote sessions, panel discussions, exhibitor showcases, and BIO One-on-One Partnering™ meetings; for more details, please refer to the official website BIO 2025.
About BIOCYTOGEN
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1 million fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2024, 200+ therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 50+ target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinica research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com/.
We look forward to seeing you at the BIO International Convention in Boston, MA!
